
Thomas Steuber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/939625/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Neurovascular Structure-adjacent Frozen-section Examination (NeuroSAFE) Increases Nerve-sparing Frequency and Reduces Positive Surgical Margins in Open and Robot-assisted Laparoscopic Radical Prostatectomy: Experience After 11 069 Consecutive Patients. European Urology, 2012, 62, 333-340.	1.9	213
2	Full Functional-Length Urethral Sphincter Preservation During Radical Prostatectomy. European Urology, 2011, 60, 320-329.	1.9	199
3	A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. European Urology, 2016, 69, 788-794.	1.9	140
4	Current Technique of Open Intrafascial Nerve-Sparing Retropubic Prostatectomy. European Urology, 2009, 56, 317-324.	1.9	129
5	Circulating Prostate Tumor Cells Detected by Reverse Transcription-PCR in Men with Localized or Castration-Refractory Prostate Cancer: Concordance with CellSearch Assay and Association with Bone Metastases and with Survival. Clinical Chemistry, 2009, 55, 765-773.	3.2	122
6	Radical prostatectomy improves progressionâ€free and cancerâ€specific survival in men with lymph node positive prostate cancer in the prostateâ€specific antigen era: a confirmatory study. BJU International, 2011, 107, 1755-1761.	2.5	105
7	A comparative study of robotâ€assisted and open radical prostatectomy in 10Â790 men treated by highly trained surgeons for both procedures. BJU International, 2019, 123, 1031-1040.	2.5	76
8	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. European Urology Focus, 2017, 3, 646-649.	3.1	72
9	Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 235.e11-235.e16.	1.6	62
10	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	1.9	58
11	Comparison of Free and Total Forms of Serum Human Kallikrein 2 and Prostate-Specific Antigen for Prediction of Locally Advanced and Recurrent Prostate Cancer. Clinical Chemistry, 2007, 53, 233-240.	3.2	57
12	Functional Outcomes and Quality of Life After Radical Prostatectomy Only Versus a Combination of Prostatectomy with Radiation and Hormonal Therapy. European Urology, 2017, 71, 330-336.	1.9	57
13	Postoperative complications of contemporary open and robotâ€assisted laparoscopic radical prostatectomy using standardised reporting systems. BJU International, 2018, 122, 801-807.	2.5	52
14	Risk assessment for biochemical recurrence prior to radical prostatectomy: Significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. International Journal of Cancer, 2006, 118, 1234-1240.	5.1	48
15	βIII-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	3.8	48
16	The 2002 AJCC pT2 Substages Confer No Prognostic Information on the Rate of Biochemical Recurrence After Radical Prostatectomy. European Urology, 2006, 49, 273-279.	1.9	45
17	Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. International Journal of Cancer, 2007, 120, 1499-1504.	5.1	41
18	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	1.9	40

THOMAS STEUBER

#	Article	IF	CITATIONS
19	Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer—Translational Research Results from the Prospective ProMPT trial. European Urology Focus, 2021, 7, 55-62.	3.1	27
20	Thrombospondin 1 and cathepsin D improve prostate cancer diagnosis by avoiding potentially unnecessary prostate biopsies. BJU International, 2019, 123, 826-833.	2.5	25
21	Development and validation of a novel multivariate risk score to guide biopsy decision for the diagnosis of clinically significant prostate cancer. BJUI Compass, 2020, 1, 15-20.	1.3	25
22	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2802-2811.	7.0	21
23	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	1.8	20
24	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2018, 74, 693-696.	1.9	19
25	Detection of Androgen Receptor Variant 7 (ARV7) mRNA Levels in EpCAM-Enriched CTC Fractions for Monitoring Response to Androgen Targeting Therapies in Prostate Cancer. Cells, 2019, 8, 1067.	4.1	18
26	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	5.3	16
27	Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer. PLoS ONE, 2017, 12, e0181557.	2.5	15
28	Comparison of intra- and postoperative analgesia and pain perception in robot-assisted vs. open radical prostatectomy. World Journal of Urology, 2020, 38, 1451-1457.	2.2	14
29	PROPOSe: A Real-life Prospective Study of Proclarix, a Novel Blood-based Test to Support Challenging Biopsy Decision-making in Prostate Cancer. European Urology Oncology, 2022, 5, 321-327.	5.4	14
30	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	2.2	10
31	Correlation of Urine Loss after Catheter Removal and Early Continence in Men Undergoing Radical Prostatectomy. Current Oncology, 2021, 28, 4738-4747.	2.2	10
32	Radical prostatectomy in oligometastatic prostate cancer. Current Opinion in Urology, 2017, 27, 572-579.	1.8	9
33	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer, 2017, 17, 504.	2.6	9
34	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	6.4	9
35	Perioperative management of direct oral anticoagulants in patients undergoing radical prostatectomy: results of a prospective assessment. World Journal of Urology, 2019, 37, 2657-2662.	2.2	6
36	Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. Asian Journal of Urology, 2022, 9, 69-74.	1.2	6

#	Article	IF	CITATIONS
37	Urethral Sphincter Length but Not Prostatic Apex Shape in Preoperative MRI Is Associated with Mid-Term Continence Rates after Radical Prostatectomy. Diagnostics, 2022, 12, 701.	2.6	3
38	A nuclear shift of GSK3β protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	1.8	2
39	Full functional-length urethral sphincter- and neurovascular bundle preservation improves long-term continence rates after robotic-assisted radical prostatectomy. Journal of Robotic Surgery, 2022, , 1.	1.8	2